Location History:
- Guangdong, CN (2007)
- Shenzhen, CN (2009)
Company Filing History:
Years Active: 2007-2009
Title: Weiming Hu: Innovator in Histone Deacetylase Inhibitors
Introduction
Weiming Hu is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of histone deacetylase inhibitors. With a total of 2 patents, his work focuses on innovative compounds that have the potential to treat various cell proliferative diseases.
Latest Patents
Weiming Hu's latest patents include groundbreaking research on benzamide derivatives. The first patent, titled "Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity," details the preparation and pharmaceutical use of novel benzamide derivatives. These compounds are designed to act as histone deacetylase inhibitors (HDACI) and are aimed at treating diseases such as cancer and psoriasis. The second patent, "Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity," reiterates the importance of these compounds in the pharmaceutical landscape, emphasizing their potential in combating cell proliferative diseases.
Career Highlights
Weiming Hu is currently associated with Shenzhen Chipscreen Biosciences, Ltd., where he continues to advance his research in the field. His work has garnered attention for its innovative approach to drug development, particularly in the area of cancer treatment.
Collaborations
Throughout his career, Weiming Hu has collaborated with notable colleagues, including Xian-Ping Lu and Zhibin Li. These collaborations have further enriched his research and contributed to the advancement of their shared goals in pharmaceutical innovation.
Conclusion
Weiming Hu stands out as a key figure in the development of histone deacetylase inhibitors, with his innovative patents paving the way for new treatments in oncology and dermatology. His contributions to Shenzhen Chipscreen Biosciences, Ltd. and his collaborations with esteemed colleagues highlight his commitment to advancing medical science.